Australia · Delayed Price · Currency is AUD Noxopharm Company Description
Noxopharm Limited, a clinical-stage biotechnology company, engages in the development of therapies for chronic inflammation, autoimmune diseases, and cancer in the Pan-Pacific region.
The company develops Sofra, a platform designed to regulate innate immune signaling with greater precision; and Chroma, a small molecule technology platform focused on the development of multiple drug candidates for cancer treatment.
It is also developing SOF-SKN, a topical therapy that has completed Phase I clinical trial for cutaneous lupus erythematosus; and CRO-67, a dual-cell preclinical drug candidate for the treatment of pancreatic cancer.
In addition, the company intends to improve mRNA vaccines. Noxopharm Limited was incorporated in 2015 and is based in Glenhaven, Australia.
Contact Details
Address: 60 Linksley Ave Glenhaven, NSW 2156 Australia | |
| Phone | 61 2 9144 2223 |
| Website | noxopharm.com |
Stock Details
| Ticker Symbol | NOX |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000NOX9 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Olivier Laczka B.S., M.Sc., Ph.D. | Chief Executive Officer |
| Shawn Pieter Van Boheemen FCPA, J.P. | Chief Financial Officer and Company Secretary |
| Jeanette Bell Ph.D. | Chief Operating Officer |